Screener
BioCryst Pharmaceuticals BCRX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from BioCryst Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's EBITDA margin?
- BioCryst Pharmaceuticals (BCRX) reported EBITDA margin of -33% in Q2 2026.
- How has BioCryst Pharmaceuticals's EBITDA margin changed year-over-year?
- BioCryst Pharmaceuticals's EBITDA margin decreased by 432.1% year-over-year, from 10% to -33%.
- What is the long-term trend for BioCryst Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's EBITDA margin has grown at a -47.5% compound annual growth rate (CAGR), from -976.9% to 39.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about BioCryst Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude